Regulation & law · 29/11/2021

AAV Isolate and Fusion Protein Patent License Exclusive Rights Considered for Atsena Therapeutics

The National Institutes of Health are considering granting exclusive rights to Atsena Therapeutics, Inc. under a non-exclusive patent license for an AAV isolate and fusion protein, comprising nerve growth factor signal peptide and parathyroid hormone, as outlined in a recent notice.